Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661316 | 0.89 | LMNA (0.56) | CYP1A2SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL29289764 | 0.84 | HPGD (0.61) | CYP1A2SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL69653 | 0.84 | MAPT (0.64) | CYP1A2SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL28220099 | 0.83 | KDM4E (0.61) | KDM4EALDH1A1HPGDTSHRLMNA | |
| SCHEMBL22485568 | 0.83 | BRD4 (0.55) | CYP1A2SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL18247275 | 0.83 | P2RX7 (0.64) | CYP1A2SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL2162898 | 0.83 | P2RX7 (0.64) | CYP1A2SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL24742673 | 0.82 | LMNA (0.46) | CYP1A2SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL9252367 | 0.81 | HPGD (0.65) | CYP1A2SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL20729906 | 0.81 | LMNA (0.57) | SMN1; SMN2NPC1RAB9ATP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-108137545-B | Triazole agonists of the APJ receptor | 美国安进公司 | 2020-09-22 | — | — | CN | disclosed |
| EP-3300500-B1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3300500-B1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221162-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| WO-2016187308-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187308-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | APH1A, BRDT, APH1B | CYP1A2 1401/4885SMN1; SMN2 4724/4885NPC1 2070/4885 |
| US-10344016-B2 | Bromotriazole intermediates | APH1A, BRDT, APH1B | CYP1A2 1401/4885SMN1; SMN2 4724/4885NPC1 2070/4885 |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | CYP1A2 218/4885SMN1; SMN2 4804/4885NPC1 1375/4885 |
| US-10221162-B2 | Triazole agonists of the APJ receptor | TBXA2R, AGTR1, AGTR2 | CYP1A2 218/4885SMN1; SMN2 4804/4885NPC1 1375/4885 |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | CYP1A2 218/4885SMN1; SMN2 4804/4885NPC1 1375/4885 |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | CYP1A2 218/4885SMN1; SMN2 4804/4885NPC1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.